Treatment of severe sleep disorder related to alcohol-dependence with high-dose agomelatine - A case report

Psychiatria Danubina

Volumn 25, Issue 4, 2013, Pages 416-418

  Grosshans, Martin ^a   Mutschler, Jochen ^b   Kiefer, Falk ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE;

AGED; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; HUMAN; INSOMNIA; MALE; RELAPSE; SLEEP; SLEEP DISORDER; SLEEP QUALITY; SLEEP TIME; WAKEFULNESS;

ACETAMIDES; AGED; ALCOHOLISM; HUMANS; HYPNOTICS AND SEDATIVES; MALE; SLEEP DISORDERS; TREATMENT OUTCOME;

EID: 84892413917     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Brower KJ: Insomnia, alcoholism and relapse. Sleep Med Rev 2003; 7:523-539.
2. Brower KJ, Aldrich MS, Robinson EA, Zucker RA, Greden JF: Insomnia, self-medication, and relapse to alcoholism. Am J Psychiatry 2001; 158:399-404.
3. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practive and research. Psychiatry Res 1989; 28:193-213.
4. De Bodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ: Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010; 9:628-642.
5. European Medicines Agency: Valdoxan: Product Characteristics. EMA, 2012.
6. Kasper S, Hamon M: Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. World J Biol Psychiatry 2009; 10:117-126.
7. Kuhlwein E, Hauger RL, Irwin MR: Abnormal nocturnal melatonin secretion and disordered sleep in abstinent alcoholics. Biol Psychiatry 2003; 54:1437-1443.
8. Montejo AL, Prieto N, Terleira A: Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PESEXDQSALSEX scale. J Psychopharmacol 2010; 24:111-120.
9. Olie JP, Kasper S: Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007; 10:661-673.
10. Papakostas GI: Tolerability of modern antidepressants. J Clin Psychiatry 2008; 69:Suppl E1:8-13.